Rotigotine transdermal system: A short review

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 421-426

  Bunten, Sabine ^a   Happe, Svenja ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Parkinson's disease; Restless legs syndrome; Rotigotine; Transdermal patch

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; NAXAGOLIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTHRALGIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TRANSFORMATION; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FALLING; FATIGUE; FLU LIKE SYNDROME; HALLUCINATION; HUMAN; INSOMNIA; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PERIPHERAL EDEMA; PHYSICAL CHEMISTRY; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SOMNOLENCE; TRANSDERMAL PATCH; TREMOR; VOMITING;

EID: 33847249488     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.421     Document Type: Review

References (26)

1. Allen RP, Picchietti D, Hening WA, et al. 2003. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med, 4:101-19.
2. Braun M, Cawello W, Horstmann R. 2005a. Lack of pharmacokinetic interactions between the dopamine agonist rotigotine and levodopa/ carbidopa [abstract]. 16th International Congress on Parkinson's Disease and Related Disorders; 2005 June 5-9. Berlin. PS002/03
3. Braun M, Cawello W, Poole K, Horstmann R. 2005b. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease [abstract]. 9th Congress of the European Federation of Neurological Societies. 2005 Sep 17-20; Athens. P1245.
4. Cawello W, Braun M, Horstmann R. 2005. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function [abstract]. 34th Annual Meeting of the American College of Clinical Pharmacology. 2005 Sep 11-13; Rockville, MD, USA. 102.
5. Coleman RJ, Lange KW, Quinn NP, et al. 1989. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphtoxazine (+PHNO): preliminary results. Mov Disord, 4:129-38.
6. Hansen K, Braun M, Horstmann R 2005. Low drug-interaction potential of rotigotine [abstract]. 34th Annual Meeting of the American College of Clinical Pharmacology. 2005 Sep 11-13; Rockville, MD, USA. 101.
7. Happe S, Trenkwalder C. 2004. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs, 18:27-36.
8. Jenner P. 2005. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology, 65(Suppl 1):S3-5.
9. LeWitt PA, Nausieda PA, Chang F, et al. 2005. Rotigotine transdermal system as adjunctive therapy to levodopa in patients with advanced-stage Parkinson's disease. Results of a randomized, double blind, placebo controlled, multicenter, multinational trial [abstract]. 9th Congress of the European Federation of Neurological Societies. 2005 Sep 17-20; Athens. SC115.
10. Loschmann PA, Chong PN, Nomoto M, et al. 1989. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal applicationof N-0437. Eur J Pharmacol, 166:373-80.
11. Metman LV, Gillespie M, Farmer C, et al. 2001. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol, 24:163-9.
12. Oertel WH, Beneš H, Geisler P, et al for the 34-center Rotigotine SP709 Study Group. 2005. Rotigotine patch efficacy and safety in the treatment of moderate to severe idiopathic restless legs syndrome - results from a multi-national double-blind placebo-controlled multi-center dose-finding study. Sleep Med, 6(Suppl 2):S159.
13. Oertel WH, Quinn NP. 1997. Parkinson's disease: drug therapy. Baillieres Clin Neurol, 6:89-108.
14. Olanow CW, Obeso JA. 2000. Preventing levodopa-induced dyskinesias. Ann Neurol, 47(Suppl 1):S167-76.
15. Pfeiffer RF. 2005. A promising new technology for Parkinson's disease. Neurology, 65(Suppl 1):S6-10.
16. Rascol O. 2005. Transdermal delivery of dopaminergic agents. Neurology, 65 (Suppl 1):S1-2.
17. Reynolds NA, Wellington K, Easthope SE. 2005. Rotigotine in Parkinson's disease. CNS Drugs, 19:973-81.
18. Stiasny K, Wetter TC, Trenkwalder C, et al. 2000. Restless legs syndrome and its treatment by dopamine agonists. Parkinsonism Relat Disord, 7:21-5.
19. Stiasny-Kolster K, Kohnen R, Schollmayer E, et al; Rotigotine Sp 666 Study Group. 2004. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of the restless legs syndrome: a double blind, placebo-controlled pilot study. Mov Disord, 19:1432-8.
20. Swart PJ, De Zeeuw RA. 1992. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie, 47:613-15.
21. The Parkinson Study Group. 2003. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol, 60:1721-8.
22. Thorpy MJ. 2005. New paradigms in the treatment of restless legs syndrome. Neurology, 64(Suppl 3):S28-33.
23. Timmerman W, Westerink BH, de Vries JB, et al. 1989. Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437. Eur J Pharmacol, 162:143-50.
24. Trenkwalder C, Paulus W, Walters AS. 2005. The restless legs syndrome. Lancet Neurology, 4:465-75.
25. Walters AS. 1995. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord, 10:634-42.
26. Watts RL, Wendt RL, Nausieda B, et al. 2004. Efficacy, safety and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord, 19(Suppl 9):S258.